## Malin A Andersson

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3089934/publications.pdf

Version: 2024-02-01

35 3,825 24 33 g-index

36 36 36 36 338

36 36 36 3338 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. European Journal of Neuroscience, 2002, 15, 120-132.	2.6	584
2	Direct Molecular Analysis of Whole-Body Animal Tissue Sections by Imaging MALDI Mass Spectrometry. Analytical Chemistry, 2006, 78, 6448-6456.	6.5	476
3	Identification of proteins directly from tissue:in situ tryptic digestions coupled with imaging mass spectrometry. Journal of Mass Spectrometry, 2007, 42, 254-262.	1.6	345
4	Striatal fosB Expression Is Causally Linked with l-DOPA-Induced Abnormal Involuntary Movements and the Associated Upregulation of Striatal Prodynorphin mRNA in a Rat Model of Parkinson's Disease. Neurobiology of Disease, 1999, 6, 461-474.	4.4	334
5	Imaging mass spectrometry of proteins and peptides: 3D volume reconstruction. Nature Methods, 2008, 5, 101-108.	19.0	225
6	Fine Mapping the Spatial Distribution and Concentration of Unlabeled Drugs within Tissue Micro-Compartments Using Imaging Mass Spectrometry. PLoS ONE, 2010, 5, e11411.	2.5	192
7	Processing MALDI mass spectra to improve mass spectral direct tissue analysis. International Journal of Mass Spectrometry, 2007, 260, 212-221.	1.5	188
8	A Novel Histology-directed Strategy for MALDI-MS Tissue Profiling That Improves Throughput and Cellular Specificity in Human Breast Cancer. Molecular and Cellular Proteomics, 2006, 5, 1975-1983.	3.8	169
9	Heat Stabilization of the Tissue Proteome: A New Technology for Improved Proteomics. Journal of Proteome Research, 2009, 8, 974-981.	3.7	137
10	Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-DOPA treatment. Neuroscience, 1999, 94, 515-527.	2.3	130
11	cAMP Response Element-Binding Protein Is Required for Dopamine-Dependent Gene Expression in the Intact But Not the Dopamine-Denervated Striatum. Journal of Neuroscience, 2001, 21, 9930-9943.	3.6	130
12	Persistent changes in striatal gene expression induced by long-terml-DOPA treatment in a rat model of Parkinson's disease. European Journal of Neuroscience, 2001, 14, 1171-1176.	2.6	120
13	Alterations in Cortical and Basal Ganglia Levels of Opioid Receptor Binding in a Rat Model of I-DOPA-Induced Dyskinesia. Neurobiology of Disease, 2001, 8, 220-239.	4.4	80
14	Quantitative mass spectrometry imaging of small-molecule neurotransmitters in rat brain tissue sections using nanospray desorption electrospray ionization. Analyst, The, 2016, 141, 3686-3695.	3.5	80
15	l-DOPA-induced Dyskinesia is Associated with Regional Increase of Striatal Dynorphin Peptides as Elucidated by Imaging Mass Spectrometry. Molecular and Cellular Proteomics, 2011, 10, M111.009308.	3.8	76
16	Neonatal Exposure to the Cyanobacterial Toxin BMAA Induces Changes in Protein Expression and Neurodegeneration in Adult Hippocampus. Toxicological Sciences, 2012, 130, 391-404.	3.1	76
17	Time course of striatal î"FosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment. European Journal of Neuroscience, 2003, 17, 661-666.	2.6	73
18	Imaging Mass Spectrometry Reveals Elevated Nigral Levels of Dynorphin Neuropeptides in L-DOPA-Induced Dyskinesia in Rat Model of Parkinson's Disease. PLoS ONE, 2011, 6, e25653.	2.5	60

#	Article	IF	CITATIONS
19	<scp>MALDI</scp> imaging of postâ€mortem human spinal cord in amyotrophic lateral sclerosis. Journal of Neurochemistry, 2013, 124, 695-707.	3.9	50
20	MALDI mass spectrometry based molecular phenotyping of CNS glial cells for prediction in mammalian brain tissue. Analytical and Bioanalytical Chemistry, 2011, 401, 135-147.	3.7	46
21	MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease. Journal of Visualized Experiments, 2012, , .	0.3	38
22	Putaminal Upregulation of FosBs?"FosB-Like Immunoreactivity in Parkinson's Disease Patients with Dyskinesia. Journal of Parkinson's Disease, 2011, 1, 347-357.	2.8	34
23	Quality Measures of Imaging Mass Spectrometry Aids in Revealing Long-term Striatal Protein Changes Induced by Neonatal Exposure to the Cyanobacterial Toxin β-N-methylamino-L-alanine (BMAA). Molecular and Cellular Proteomics, 2014, 13, 93-104.	3.8	34
24	Expression pattern of JunD after acute or chronic l-DOPA treatment: Comparison with $\hat{l}$ FosB. Neuroscience, 2007, 144, 198-207.	2.3	24
25	Reduced <i>Vglut2/Slc17a6</i> Gene Expression Levels throughout the Mouse Subthalamic Nucleus Cause Cell Loss and Structural Disorganization Followed by Increased Motor Activity and Decreased Sugar Consumption. ENeuro, 2016, 3, ENEURO.0264-16.2016.	1.9	23
26	Intra―and interregional coregulation of opioid genes: broken symmetry in spinal circuits. FASEB Journal, 2017, 31, 1953-1963.	0.5	21
27	Region-specific bioconversion of dynorphin neuropeptide detected by in situ histochemistry and MALDI imaging mass spectrometry. Peptides, 2017, 87, 20-27.	2.4	19
28	Macrophage migration inhibitory factor (MIF) modulates trophic signaling through interaction with serine protease HTRA1. Cellular and Molecular Life Sciences, 2017, 74, 4561-4572.	5.4	19
29	Analysis of Neuropeptides by MALDI Imaging Mass Spectrometry. Methods in Molecular Biology, 2013, 1023, 121-136.	0.9	12
30	Perinatal exposure to a glyphosate-based herbicide causes dysregulation of dynorphins and an increase of neural precursor cells in the brain of adult male rats. Toxicology, 2021, 461, 152922.	4.2	12
31	Neuropeptide imaging in rat spinal cord with MALDI-TOF MS: Method development for the application in pain-related disease studies. European Journal of Mass Spectrometry, 2017, 23, 105-115.	1.0	11
32	Opioid precursor protein isoform is targeted to the cell nuclei in the human brain. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 246-255.	2.4	6
33	MALDI Imaging and Profiling Mass Spectrometry in Neuroproteomics. Frontiers in Neuroscience, 2009, , 115-134.	0.0	1
34	Chapter 3.2 Microdialysis coupled with liquid chromatography/mass spectrometry. Handbook of Behavioral Neuroscience, 2006, 16, 251-266.	0.7	0
35	Dynorphins in neurological and mental disorders. Pharmacological Reports, 2011, 63, 207.	3.3	0

3